Results of Topotecan Single-Agent Therapy in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

References

• Beran M. Treatment of myelodysplastic syndromes. Therapy of Hematopoietic Neoplasia, E Freireich, H Kantarjian. Dekker, New York 1991; 35–82
   Google Scholar
• Bennett J.M. Classification of the myelodysplastic syndromes. Clinical Haematology 1986; 15: 909–923
   PubMedGoogle Scholar
• Aul C., Gattermann N., Germing U., Runde V., Heyll A., Schneider W. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia 1994; 8: 1906–1913
   PubMed Web of Science ®Google Scholar
• Morel P., Hebbar K., Lai J-L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Fenaux P. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system. A report on 408 cases. Leukemia 1993; 7: 1315–1324
   PubMed Web of Science ®Google Scholar
• Bennett J.M, Catovsky D., Daniel M.T, Flandrin G., Gaiton D., Gralnick H., Sultan C., Cox C. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. British Journal of Haematology 1994; 87: 746–754
   PubMed Web of Science ®Google Scholar
• Michaux J.L, Martiat P. Chronic myelomonocytic leukaemia (CMML): a myelodysplastic or myeloproliferative syndrome?. Leukemia and Lymphoma 1993; 9: 3–5
   Web of Science ®Google Scholar
• Kantarjian H.M, Keating M.J, Waiters R.S, McCredie K.B, Smith T.L, Talpaz M., Beran M., Cork A., Trujillo J.K., Freireich E.J. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58: 2023–2030
   PubMed Web of Science ®Google Scholar
• Giles F.J, Hamon M.D., Newland A.C. Transient response to alpha-2b-interferon in patients with myelodysplasia [abstract]. British Journal of Haematology 1988; 69: 123
   Web of Science ®Google Scholar
• Koeffler B.P, Heitlan D., Mertelsmann R., Kolitz J.E, Schulman P., Itri L., Gunter P., Besa E. Randomized study of 13-cis-retin acid versus placebo in the myelodysplastic disorders. Blood 1987; 71: 703–708
   Web of Science ®Google Scholar
• Clark R.E, Ismail S.A.D., Jacobs A., West R.R. A randomized trial of 13-cis-retinoic acid with or without cytosine arabinoside in patients with myelodysplastic syndrome. British Journal of Haematology 1987; 66: 77–83
   PubMed Web of Science ®Google Scholar
• Arcenas A.G, Vadhan-Raj S. Hematopoietic growth factor therapy of myelodysplastic syndromes. Leukemia and Lymphoma 1993; 11: 65–69
   PubMed Web of Science ®Google Scholar
• Gerhartz H.H, Marcus R., Delmer A., Zwierzina H., Suciu S., Dardenne M., Solbu G., deWitte T., Jacobs A., Visani G. A randomized phase II study of low-dose cytosine arabinoside (LD-Ara-C) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 1994; 8: 16–23
   PubMed Web of Science ®Google Scholar
• Cheson B.D, Jasperse D.M, Simon R., Friedman M.A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology 1986; 4: 1857–1864
   PubMed Web of Science ®Google Scholar
• Greenberg B.R, Reynolds R., Charron C.B, Squillace K.M, Lessin L.S, Case D.C., Gams R.A. Treatment of myelodysplastic syndromes with daily oral Idarubicin. Cancer 1993; 71: 1989–1992
   PubMed Web of Science ®Google Scholar
• Fenaux P., Morel P., Rose C., Lai J.L, Jouet J.P., Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology 1991; 77: 497–501
   PubMed Web of Science ®Google Scholar
• Estey E., Pierce S., Kantarjian H., O'Brien S., Beran M., Andreeff M., Escudier S., Roller C., Kornblau S., Robertson L., Keating M. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leukemia and Lymphoma 1993; 11(Suppl 1)59–63
   PubMed Web of Science ®Google Scholar
• DeWitte T., Zwaan F., Hermans H., Vernant J., Kolb H., Vossen J., Lonnqvist B., Beelen D., Ferrant A., Gmur J. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Bone Marrow Transplantation 1989; 4(Suppl 3)38–39
   Google Scholar
• Anderson J.E, Appelbaum R., Schoch G., Gooley T., Anasetti C., Bensinger W.I, Bryant E., Buckner C.D, Chauncey T., Clift R.A, Deeg H.J, Doney K., Flowers M., Hansen J.A., Martin P.J, Matthews D.C, Nash R.A, Sanders J.E, Shulman H., Sullivan K.M, Witherspoon R.P., Storb R. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. Journal of Clinical Oncology 1996; 14: 220–226
   PubMed Web of Science ®Google Scholar
• Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• Giovanella B.C, Stehlin J.S, Wall M.E, Wani M.C, Nicholas A.W, Liu L.F, Silber R., Potsmeil M. DNA topoisomerase target chemotherapy of human colon cancer xenografts. Science 1989; 246: 1046–1048
   PubMed Web of Science ®Google Scholar
• Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N. A phase II study of CTP-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. Journal of Clinical Oncology 1992; 10: 16–20
   PubMed Web of Science ®Google Scholar
• Shimada Y., Yoshino M., Wakui A., Nakao I., Futatsuki K., Sakata Y., Kambe M., Taguchi T., Ogawa N. Phase II study of CPT-11 a new camptothecin derivative, in patients with metastatic colorectal cancer [abstract]. Proceedings of the American Society of Clinical Oncology 1991; 10: 909–913
   Google Scholar
• Ohno R., Okada K., Masaoka T., Kuramoto A., Arima T., Yoshida Y., Ariyoshi H., Ichimaru M., Sakai Y., Oguro M. An early phase II study of CPT-11 a new derivative of camptothecin for the treatment of leukemia and lymphoma. Journal of Clinical Oncology 1990; 8: 1907–1912
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M, Beran M., Ellis A., Zwelling L., O'Brien S., Cazenave L., Roller C., Rios M.B, Plunkett W., Keating M.J, Estey E.H. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed leukemia. Blood 1993; 81: 1146–1151
   PubMed Web of Science ®Google Scholar
• Rowinsky E.K, Adjei A., Donehower R.C, Gore S.D, Jones R.J., Burke Pi., Cheng Y-C, Gorchow L.B, Kaufmann S.H. Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology 1994; 12: 2193–2203
   PubMed Web of Science ®Google Scholar
• Estey E., Keating M.J, Dixon D., Trujillo J.M, McCredie K.B, Freireich E. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic myelogenous leukemia. Hematological Pathology 1987; 1: 203–208
   PubMedGoogle Scholar
• Beran M., Kantarjian H., O'Brien S., Roller C., Albitar M., Arbuck S., Pierce S., Moore M., Abbruzzese J., Andreeff M., Keating M., Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473–2479
   PubMed Web of Science ®Google Scholar
• Trujillo J.M, Cork A., Ahearn M.J. Hematologic and cytologic characteristics of 8;21 translocation acute granulocytic leukemia. Blood 1979; 53: 695–706
   PubMed Web of Science ®Google Scholar
• LeMaistre A., Lee M.S, Talpaz M., Kantarjian H.M, Freireich E.J, Deisseroth A.B, Trujillo J.K., Stass R.A. RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 1989; 73: 889–891
   PubMed Web of Science ®Google Scholar
• Nakagawa T., Saitoh S., Imoto S., Itoh M., Tsutsumi M., Hikiji R., Nakamura H., Matozaki S., Ogawa R., Nakao Y. Multiple point mutations of N-ras and K-ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49: 114–122
   PubMed Web of Science ®Google Scholar
• Erlich H., Bugawan T., Begovich A.B, Scharf S., Griffith R., Saiki R., Higuchi R., Walsh P.S. HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. European Journal of Immunogenetics 1991; 18: 33–55
   PubMedGoogle Scholar
• Cai S.P, Wall J., Kan Y.W, Chehab YW. Reverse dot blot probes for the screening of beta-thalassemia mutations in Asians and American blacks. Human Mutation Journal 1994; 3: 59–63
   PubMed Web of Science ®Google Scholar
• Cuppens H., Marynen P., De Boeck C., Cassiman J.J. Detection of 98.5% of the mutations in 200 Belgian cystic fibrosis alleles by reverse dot-blot and sequencing of the complete coding region and exon-intron junctions of the CFTR gene. Genomics 1993; 18: 693–697
   PubMed Web of Science ®Google Scholar
• Silverman L., Holland J., Weinberg R., Alter B., Davis B., Ellison R., Demakos E., Cornell C., Carey R., Schiffer C., Frei E., McIntyre O.R. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7: 21–29
   PubMed Web of Science ®Google Scholar
• National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions, Bethesda MD. Division of Cancer Institute. 1988
   Google Scholar
• Gehan E. The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 1961; 13: 346–353
   PubMedGoogle Scholar
• Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. Journal of American Statistical Association 1958; 53: 457–482
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Report 1966; 50: 163–170
   PubMedGoogle Scholar
• Raza A., Gezer S., Mundle S., Gao X-Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chaney C., Showel J., Gregory S., Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
   PubMed Web of Science ®Google Scholar
• Leith C.P, Kopecky K.J, Godwin J., McConnell T., Slovak M.L, Chen I.M, Head D.R, Appelbaum F.R., Willman C.L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Pinto A., Zagonel V. 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present, and future trends. Leukemia 1993; 7: 51–60
   PubMed Web of Science ®Google Scholar
• Anzai H., Frost P., Abbruzzese J.L. Synergistic cytotoxicity with 2′-deoxy-5- and topotecan in vitro and in vivo. Cancer Research 1992; 52: 2180–2185
   PubMed Web of Science ®Google Scholar
• Cogswell PC., Morgan R., Dunn M., Neubauer A., Nelson P., Polland-Johnston N.K, Sandberg A.A., Liu E. Mutations of the RAS proto-oncogenes in chronic myelogenous leukemias: a high frequency of RAS mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74: 2629–2633
   PubMed Web of Science ®Google Scholar
• Ginsberg C.H, LeMaistre A.C, Kantarjian H., Talpaz M., Cork A., Freireich E., Trujillo J.M, Lee M-S., Stass S.A. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 1990; 76: 1214–1219
   PubMed Web of Science ®Google Scholar
• Seiter K., Feldman E.J, Halicka D., Trananos F., Zbigniew D., Lake D., Ahmed T. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of Clinical Oncology 1997; 15: 44–51
   PubMed Web of Science ®Google Scholar